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Abstract
Background  and  objectives:  Postoperative  bleeding  has  a  great  clinical  importance  and  can  con-
tribute to  increased  mortality  and  morbidity  in  patients  undergoing  coronary  artery  bypass  graft
surgery.  In  this  prospective,  randomized,  double-blind  study,  we  evaluated  the  effect  of  pro-
phylactic  administration  of  ﬁbrinogen  concentrate  on  post-coronary  artery  bypass  graft  surgery
bleeding.
Methods:  A  total  of  60  patients  undergoing  coronary  artery  bypass  surgery  were  randomly
divided into  two  groups.  Patients  in  the  ﬁbrinogen  group  received  1  g  of  ﬁbrinogen  concentrate
30  min  prior  to  the  operation,  while  patients  in  the  control  group  received  placebo.  Post-
operative  bleeding  volumes,  prothrombin  time,  partial  thromboplastin  time,  INR,  hemoglobin
and  transfused  blood  products  in  both  groups  were  recorded.  A  strict  red  blood  cell  transfusion
protocol  was  used  in  all  patients.
Results: There  were  no  signiﬁcant  differences  between  intra-operative  packed  red  blood  cells
infusion  in  the  studied  groups  (1.0  ±  1.4  in  ﬁbrinogen  group,  and  1.3  ±  1.1  in  control  group).
Less  postoperative  bleeding  was  observed  in  the  ﬁbrinogen  group  (477  ±  143  versus  703  ±  179,
p  =  0.0001).  Fifteen  patients  in  the  ﬁbrinogen  group  and  21  in  the  control  group  required  post-
op  packed  red  blood  cells  infusion  (p  =  0.094).  No  thrombotic  event  was  observed  through  72  h
after  surgery.
Conclusion:  Prophylactic  ﬁbrinogen  reduces  post-operative  bleeding  in  patients  undergoing
coronary artery  bypass  graft.
© 2013  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  
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Estudo  randômico  e  duplo-cego  de  proﬁlaxia  com  ﬁbrinogênio  para  reduzir  o
sangramento  em  cirurgia  cardíaca
Resumo
Justiﬁcativa  e  objetivo:  A  hemorragia  no  período  pós-operatório  é  de  grande  importância
clínica e  pode  contribuir  para  o  aumento  da  morbidade  e  mortalidade  em  pacientes  submetidos
à  cirurgia  de  revascularizac¸ão  coronária.  Nesse  estudo  prospectivo,  randômico  e  duplo-cego,
avaliamos  o  efeito  da  administrac¸ão  proﬁlática  de  concentrado  de  ﬁbrinogênio  sobre  o  sangra-
mento  após  cirurgia  de  revascularizac¸ão  coronária.
Métodos:  No  total,  60  pacientes  submetidos  à  cirurgia  de  revascularizac¸ão  coronária  foram
randomicamente divididos  em  dois  grupos.  Os  pacientes  do  grupo  ﬁbrinogênio  receberam  1  g
de  concentrado  de  ﬁbrinogênio  30  minutos  antes  da  operac¸ão,  enquanto  os  doentes  do  grupo
controle  receberam  placebo.  Os  volumes  de  sangramento  no  pós-operatório,  tempo  de  pro-
trombina,  tempo  de  tromboplastina  parcial,  INR,  hemoglobina  e  hemoderivados  transfundidos
em  ambos  os  grupos  foram  registrados.  Um  protocolo  de  conduta  rigoroso  para  transfusão  de
hemácias  foi  usado  em  todos  os  pacientes.
Resultados:  Não  houve  diferenc¸as  signiﬁcantes  entre  as  infusões  de  concentrados  de  hemácias
nos grupos  estudados  (1,0  ±  1,4  no  grupo  ﬁbrinogênio  e  1,3  ±  1,1  no  grupo  controle).  O  grupo
ﬁbrinogênio  apresentou  menos  sangramento  no  pós-operatório  (477  ±  143  versus  703  ±  179,
p  =  0,0001).  Quinze  pacientes  do  grupo  ﬁbrinogênio  e  21  do  grupo  controle  precisaram  de  infusão
de  concentrado  de  hemácias  no  pós-operatório  (p  =  0,094).  Evento  trombótico  não  foi  observado
durante  72  h  após  a  cirurgia.
Conclusão:  Proﬁlaxia  com  ﬁbrinogênio  reduz  o  sangramento  no  período  pós-operatório  de
pacientes submetidos  à  revascularizac¸ão  coronária.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  
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ptimal  prevention  and  management  of  intra-  and  post-
perative bleeding  has  a  great  clinical  importance  in  various
ypes of  surgeries,  including  coronary  artery  bypass  graft
urgery (CABG).  Such  management  can  efﬁciently  decrease
he amount  of  blood  products  transfusion  and  as  a  result,
ay lead  to  less  transfusion  related  complications.
Two  to  6  percent  of  CABG  surgery  patients  would  be  re-
xplored due  to  intraorpost-operative  hemorrhage,  which
an lead  to  high  morbidity  and  mortality  rates.  Further-
ore, complications  such  as  sternal  wound  infections  are
ore frequent  along  with  post-operative  transfusion.1--2
onsequently,  the  importance  of  any  approach  or  inter-
ention to  decrease  intra-  or  post-operative  hemorrhage
s obvious.2 Coagulopathy  is  one  possible  reason  of  exces-
ive bleeding  during  and  following  surgery.  Multiple  factors
ncluding platelet  dysfunction,  ﬁbrinolysis  and  coagulation
actor deﬁciencies  may  affect  post-operative  bleeding  fol-
owing  cardiac  surgery.3
During  CABG  surgery,  low  ﬁbrinogen  plasma  concen-
ration may  directly  be  associated  with  blood  loss.4 This
ssociation is  likely  since  ﬁbrinogen  is  essential  in  the  cross-
inking of  platelets  during  primary  hemostasis  and  plays  a
entral role  in  the  coagulation  cascade,5 and  it  had  been
hown that  following  hemorrhage,  ﬁbrinogen  concentration
ecreases more  than  other  coagulationfactors.6--9
The  purpose  of  present  study  was  to  investigate  the
ffect of  pre-operative  infusion  of  ﬁbrinogen  concentrate  on
ost-operative bleeding  volume  in  CABG  surgery  patients.
he percentage  and  amount  of  transfused  blood  products
ere considered  as  secondary  outcome  parameters.
t
a
w
pethods
ollowing  the  approval  of  the  study  protocol  by  the  Insti-
utional Ethics  Committee,  this  trial  was  registered  by  the
ranian Registry  of  Clinical  Trial.  All  participants  provided  a
ritten form  of  consent  after  they  were  fully  informed  of
ature and  design  of  the  study.
Sixty  patients,  scheduled  for  ﬁrst  time  elective  CABG,
ere enrolled  in  this  double-blinded  randomized  placebo-
ontrolled clinical  trial.  The  patients  with  the  following
riteria were  not  considered  eligible  to  take  part  in  this
tudy: previously  diagnosed  hematologic  or  liver  diseases,
ncontrolled or  insulin  dependent  diabetes,  pregnancy,
nstable angina,  serum  creatinine  more  than  130  mol/L,
eft ventricular  ejection  fraction  less  than  35%,  serum  ﬁb-
inogen levels  more  than  3.5  g/L.  The  patients  also  needed
o be  mentally  capable  of  giving  a  written  informed  consent.
Using  a computer  generated  randomization  list,  patients
ere assigned  to  ﬁbrinogen  and  control  groups.  All  the
equired study  drugs  were  prepared  by  an  anesthetist  who
as not  involved  in  the  surveillance  of  the  patients.  Fur-
hermore, all  the  ﬂuid  plastic  containers  were  covered  by
extile, so  content  of  plastic  containers  was  invisible.
Anticoagulant  therapy  with  aspirin,  warfarin  and  clopi-
ogrel was  discontinued  48  h prior  to  surgery.  On  arrival  to
he operating  room,  all  the  patients  received  oxygen  via  a
acemask at  a  rate  of  4  L/min,  and  an  18-gauge  intravenous
atheter was  placed  in  a  peripheral  vein  to  allow  for  hydra-
Este é um artigo Open Access sob a licença de CC BY-NC-NDion of  the  patients  using  lactated  ringer’s  solution  (7  mL/kg)
nd administration  of  medications.  Standard  monitoring
hich consisted  of  invasive  and  non-invasive  arterial  blood
ressure, heart  rate,  electrocardiogram,  pulse  oximetry,
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pFibrinogen  decreases  post-CABG  bleeding  
and  capnometery  was  initiated  and  continued  throughout
anesthesia.
Anesthesia was  induced  by  1  mg  of  IV  midazolam,  8  g/kg
of IV  fentanyl  and  3  mg/kg  of  IV  sodium  thiopental,  and
0.1 mg/kg  of  IV  pancuronium  bromide.  Prior  to  the  start
of surgery  a  percutaneous  central  venous  line  was  placed.
Isoﬂurane was  used  for  maintaining  general  anesthesia.
Before beginning  of  cardiopulmonary  bypass,  a  baseline  acti-
vated clotting  time  (ACT)  was  measured  and  an  IV  bolus
dose of  heparin  (400  U/kg)  was  administered  to  all  patients.
Next heparin  dosing  was  targeted  to  maintain  ACT  values
more than  480  seconds.  Myocardial  protection  techniques
were identical  in  both  groups,  and  priming  of  the  blood  car-
dioplegialine was  performed  on  CPB  with  autologous  blood.
Identical ﬂuid  therapy  was  used  in  both  groups.
In  the  ﬁbrinogen  group  the  patients  received  1  gram  of
ﬁbrinogen dissolved  in  50  mL  of  normal  saline  over  a  15  min
period 30  min  before  induction  of  anesthesia.  In  the  control
group the  patients  were  administered  the  same  volume  of
normal saline  during  the  same  period  of  time  as  a  placebo.
All the  drugs  were  prepared  and  administered  by  an  anes-
thetist who  was  not  anyhow  involved  in  the  study.
Hemoglobin  concentration,  platelet  count,  partial
thromboplastin time  (PTT),  prothrombin  time  (PT)  and
plasma ﬁbrinogen  concentrations  were  measured  before
induction of  general  anesthesia  and  were  repeated  again
24 h  following  surgery.  Plasma  concentrations  of  ﬁbrinogen
were adjusted  to  a  standard  hematocrit  of  40%  accord-
ing to  the  formula:  corrected  concentration  =  measured
concentration ×  (standard  hematocrit/measured  hemat-
ocrit). Hematocrit  levels  were  measured  every  30  min  until
termination of  bypass.  Red  blood  cells  were  transfused  if
the intraoperative  hematocrit  was  less  than  20%.  In  the
intensive care  unit,  hematocrit  values  less  than  25%  were
considered as  transfusion  trigger.  Plasma  was  administered
in patients  with  ongoing  bleeding  and  abnormal  PT  or
PTT. Platelets  were  transfused  with  ongoing  bleeding  and
platelets count  less  than  7  ×  109 per  liter.Post-operative  bleeding  was  described  as  the  overall
chest tube  drainage  during  the  ﬁrst  12  post-operative  hours
and was  recorded  by  a  trained  intensive  care  nurse.  The
amount of  transfused  packed  red  blood  cells,  fresh  frozen
t
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Table  1  Basic  characteristics  of  the  patients  and  baseline  coagul
Female/male  
Age (years)  
Weight  (kg)  
Height  (cm)  
Base  line  ﬁbrinogen  (g  L−1)  
Aortic  clamp  time  (min)  
Anastomoses  (numbers)  
Post-op  packed  red  blood  cell  transfusion  (n)  
Heparin  (units  administered)  
Baseline  hemoglobin  (g  L−1)  
PTT  (s)  
PT  (s)
Platelets  (L−1)  
a Data were presented mean ± SD.
b There is no signiﬁcant difference between groups.255
lasma,  and  platelets  during  the  ﬁrst  24  h  post-surgery  were
lso documented.  For  a  period  of  72  h  following  surgery  clin-
cal signs  and  symptoms  of  thrombotic  adverse  effects  were
ollowed and  recorded.  If  any  of  these  events  occurred,  the
atient was  considered  a  candidate  for  further  evaluation
uch as  Doppler  ultrasound.
tatistics
t  was  determined  that  a  sample  size  of  18  patients  in  each
roup would  be  sufﬁcient  to  detect  a  minimum  of  200  mL
leeding differences  in  12  h  following  surgery  with  a  stan-
ard deviation  of  150  mL,  power  of  90%  and  a  signiﬁcant
evel of  0.01.
Statistical analysis  of  the  data  was  performed  using  SPSS
or windows  version  17  (SPSS,  Chicago,  IL).  The  distribution
f data  was  checked  by  Kolmogorov--Simonov  test,  which
onsisted of  a  normal  distribution.  Group  comparisons  were
erformed  with  two-sample  t-tests  for  continuous  data.  Sex
as compared  by  2 test.  Statistical  signiﬁcance  was  deﬁned
s a  p-value  <  0.05.
esults
 total  of  60  patients  (70%  male,  30%  female)  were  enrolled
n this  study.  There  was  no  protocol  violation  and  all  of
he participants  were  included  in  the  analysis.  Basic  char-
cteristics of  the  participants  such  as  age,  weight,  height,
ortic clamp  time  and  number  of  anastomoses  were  similar
etween both  groups  (Table  1).  Baseline  and  post-operative
aboratory variables  including  PTT,  PT,  hemoglobin  concen-
ration and  platelet  count  in  both  ﬁbrinogen  and  control
roups were  similar  (Table  2).
Post-operatively,  a  lower  blood  loss  was  observed  in  the
brinogen group  (477  ±  143)  in  comparison  with  the  con-
rol group  (703  ±  179)  (p  <  0.0001)  (Fig.  1).  Fifteen  (50%)
atients in  the  ﬁbrinogen  group  and  21  (70%)  patients  in
he control  group  received  packed  red  blood  cells  post-
peratively, and  there  were  no  signiﬁcant  differences  in
roups (p  =  0.094).  Yet,  total  amount  of  packed  red  blood
ells infusion  in  groups  did  not  differ  signiﬁcantly  (p  =  0.096).
ation  values.
Fibrinogen  group  Control  group
10/20  8/22
59  ±  9  58  ±  9
73  ±  14  71  ±  11
164  ±  8.9  164.6  ±  6.9
2.7  ±  0.3  2.7  ±  0.3
52.2  ±  12.1  56.8  ±  8.0
2.8  ±  0.4  2.6  ±  0.4
1.5  ±  1.8  2.0  ±  1.5
34,000  ±  9500  36,000  ±  11,000
13.8  ±  1.5  13.6  ±  1.6
29.9  ±  6.4  28.8  ±  6.6
12.4  ±  0.9  12.4  ±  0.7
2,570,000  ±  99,223  255,733  ±  56,774
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Table  2  Coagulation  at  postoperative  day  1.
Post-operative  value  Fibrinogen  group  Control  group
Hemoglobin  (g  dL−1) 9.7  ±  1.39 8  ±  1.2
PTT (s)  40.5  ±  25.2  44.7  ±  18.1
PT (s)  15.6  ±  8.5  14.6  ±  2.1
Platelets (L−1)  1,670,000  ±  55,000  1,680,000  ±  54,000
Fibrinogen (g  dL−1)  2.9  ±  0.4  2.9  ±  0.4
a Data were presented as mean ± SD.
b There is no signiﬁcant difference in groups.
1200
1000
800
600
400
200
0
0
1 2
Po
st
-o
pe
ra
tiv
e
 b
le
ed
in
g 
(m
L)
Figure  1  Post-operative  bleeding  (the  overall  chest  tube
drainage during  the  ﬁrst  12  post-operative  hours)  in  the  ﬁb-
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iinogen group  (1)  compared  to  the  control  group  (2).
here  were  no  signiﬁcantly  differences  in  the  number  of
acked red  blood  cells  infusion  in  groups  (1.5  ±  1.8  in  the
brinogen group,  and  2.0  ±  1.5  in  the  control  group).  Four
atients in  the  ﬁbrinogen  group  received  fresh  frozen  plasma
o in  comparison  to  2  in  the  control  group  (ns).  Only  one  of
atients in  the  ﬁbrinogen  group  received  a  platelet  transfu-
ion.
In neither  of  groups  any  clinically  apparent  thrombotic
vents were  found.
iscussion
his  study  showed  that  the  immediate  preoperative  adminis-
ration of  ﬁbrinogen  concentrates  to  CABG  surgery  patients
an decrease  post-operative  hemorrhage.
Surgical  bleeding  is  a  major  concern  in  cardiac  surgery.10
reventing  blood  product  transfusion  and  decreasing  hem-
rrhage dependent  re-exploration  rates  improve  patients’
utcomes and  could  lower  the  overall  burden  on  health  care
osts.11
Relatively  low  ﬁbrinogen  concentrations  may  play  an
mportant role  in  bleeding  following  cardiac  surgery.12,13
ow  preoperative  ﬁbrinogen  level  has  been  found  to  be
n independent  predictor  of  post-operative  bleeding  and
ransfusion,13 low  ﬁbrinogen  levels  during  and  after  CABG
urgery were  found  to  be  associated  with  bleeding14,15nd  ﬁbrinogen  administration  after  cardiopulmonary  bypass
educed the  bleeding  signiﬁcantly.16 And  last  but  not  least,
n the  so  far  only  small  prospective  randomized  study,  Karls-
on et  al.  showed  in  20  patients  that  the  preoperative
C
Tdministration  of  2  g  of  ﬁbrinogen  decreased  postoperative
lood loss  and  minimized  the  decrease  of  the  hemoglobin
oncentration postoperatively.13 Our  study  conﬁrms  these
esults and  expands  the  knowledge  in  a  larger  group  of  60
atients in  that  already  the  administration  of  1  g  of  ﬁbrino-
en is  capable  of  reducing  postoperative  bleeding  in  patients
ndergoing ﬁrst  time  CABG  surgery.
Karlsson  et  al.  also  looked  at  thrombotic  complications
nd concluded  that  the  administration  of  2  g of  ﬁbrinogen
as safe  in  this  regard.12 We  conﬁrm  this  conclusion  in  a
arger group  of  patients  although  we  only  assessed  clinical
hrombotic events.  We  thus  concluded  that  prophylac-
ic ﬁbrinogen  infusion  signiﬁcantly  reduces  post-operative
leeding without  clinical  adverse  events.  Yet,  the  investiga-
ion of  Karlson  et  al.  was  a  pilot  study  and  only  10  patients
articipated in  it.  So,  the  power  of  study  is  not  sufﬁcient  to
ake a  strong  conclusion.  In  our  study,  prophylactic  adminis-
ration of  the  lower  amount  of  ﬁbrinogen  (1  g)  could  reduce
he post-operative  blood  loss  by  32%;  however,  the  decrease
n a  blood  transfusion  was  not  signiﬁcant  but  there  was  a
rend.
In our  study,  the  packed  red  blood  cells  infusion  was
ot different  statistically  in  groups;  however,  based  on  cal-
ulated p value  (p  =  0.096),  it  is  possible  that  the  power
f the  study  was  not  sufﬁcient  to  show  such  a  differ-
nce. As  the  present  sample  size  was  estimated  considering
ost-operative hemorrhage  as  a  primary  outcome,  a  higher
owered study  is  necessary  to  assess  the  effect  of  ﬁbrinogen
oncentrate administration  on  post-CABG  packed  red  blood
ells infusion.
There are  limitations  of  this  study  such  as  the  lack  of  any
orm of  thromboelastometric  monitoring  (TEG  or  ROTEM)
erioperatively and  the  ﬁxed  dose  (1  g)  of  ﬁbrinogen.  Future
tudies with  individualized  and  more  precise  coagulation
onitoring are  needed  to  deﬁne  the  optimal  dose  of  ﬁb-
inogen. The  rationale  for  choosing  the  present  dosage  was
ased on  a  previous  study  conducted  by  Karlsson  et  al.13
nd  due  to  the  fact  that  the  plasma  ﬁbrinogen  level  was
ot evaluated  frequently  in  our  study  aiming  at  decreasing
he postoperative  blood  loss  along  with  minimal  thrombotic
dverse effects.
In conclusion,  administration  of  1  g  of  intravenous  ﬁb-
inogen concentrate  before  induction  of  general  anesthesia
n CABG  surgery  can  reduce  post-operative  bleeding.onﬂicts of  interest
he  authors  declare  no  conﬂicts  of  interest.
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